TABLE 5.

Activity of omadacycline and comparator antimicrobial agents when tested against bacterial isolates from community-acquired respiratory tract infections in the United States and Europe, SENTRY Program, 2016 to 2018

Antimicrobial agent (no. of isolates tested)	MIC (mg/liter)			% S/% Ra
	50%	90%	Range	CLSI	EUCAST
Streptococcus pneumoniae (2,626)
Omadacycline	0.06	0.12	≤0.015 to 1	98.7b /0.1
Tetracycline	0.5	>4	≤0.25 to >4	78.2/21.4	78.2/21.4
Amoxicillin-clavulanate	≤0.03	2	≤0.03 to >4	94.4/3.0	81.7/14.0
Ceftriaxone	0.03	1	≤0.015 to >2	96.5c /0.5	86.2/0.5
Clindamycin	≤0.25	>2	≤0.25 to >2	83.9/15.7	84.3/15.7
Erythromycin	0.03	>16	≤0.015 to >16	65.6/34.0	65.6/34.0
Levofloxacin	1	2	0.25 to >4	98.3/1.4	98.3/1.7
Linezolid	1	2	≤0.12 to 2	100.0/—	100.0/0.0
Penicillin	0.03	2	≤0.008 to >4	66.5d /12.5	66.5/4.5
Trimethoprim-sulfamethoxazole	0.25	>4	≤0.12 to >4	72.6/17.7	77.7/17.7
Vancomycin	0.25	0.5	≤0.06 to 0.5	100.0/—	100.0/0.0
Penicillin resistant (MIC, ≥2 mg/liter) (328)
Omadacycline	0.06	0.12	0.03 to 0.25	97.9b /0.0
Tetracycline	>4	>4	≤0.25 to >4	42.7/57.0	42.7/57.0
Amoxicillin-clavulanate	2	>4	0.5 to >4	55.5/23.8	1.5/86.3
Ceftriaxone	1	2	0.25 to >2	72.3c /4.3	7.9/4.3
Clindamycin	≤0.25	>2	≤0.25 to >2	50.6/49.1	50.9/49.1
Erythromycin	>16	>16	≤0.015 to >16	20.1/79.6	20.1/79.6
Levofloxacin	1	2	0.5 to >4	97.9/1.5	97.9/2.1
Linezolid	1	2	0.25 to 2	100.0/—	100.0/0.0
Penicillin	2	4	2 to >4	0.0d/100.0	0.0/100.0
Trimethoprim-sulfamethoxazole	>4	>4	≤0.12 to >4	27.7/64.0	32.9/64.0
Vancomycin	0.25	0.5	0.12 to 0.5	100.0/—	100.0/0.0
Tetracycline resistant (561)
Omadacycline	0.06	0.12	≤0.015 to 1	97.0b /0.2
Tetracycline	>4	>4	4 to >4	0.0/100.0	0.0/100.0
Amoxicillin-clavulanate	0.25	4	≤0.03 to >4	81.1/8.9	61.0/31.4
Ceftriaxone	0.25	2	≤0.015 to >2	86.5c /2.1	65.1/2.1
Clindamycin	>2	>2	≤0.25 to >2	33.7/65.1	34.9/65.1
Erythromycin	>16	>16	≤0.015 to >16	12.8/86.1	12.8/86.1
Levofloxacin	1	2	0.25 to >4	98.2/1.4	98.2/1.8
Linezolid	1	2	0.25 to 2	100.0/—	100.0/0.0
Penicillin	0.25	4	2 to >4	26.2d /33.3	26.2/73.8
Trimethoprim-sulfamethoxazole	1	>4	≤0.12 to >4	41.7/36.7	54.0/36.7
Vancomycin	0.25	0.5	≤0.06 to 0.5	100.0/—	100.0/0.0
Haemophilus influenzae (1,575)
Omadacycline	0.5	1	≤0.12 to 16	99.6f/0.1
Tetracycline	0.5	1	0.12 to >8	99.4/0.6	99.1/0.6
Amoxicillin-clavulanate	0.5	2	≤0.06 to >8	99.6/0.4	93.4/6.6
Ampicillin	0.5	>8	≤0.12 to >8	66.5/26.0	66.5/33.5
Azithromycin	1	2	≤0.12 to >8	99.0/—	99.0/—
Ceftriaxone	0.004	0.015	≤0.002 to 0.5	100.0/—	99.7/0.3
Levofloxacin	0.015	0.03	0.008 to >2	99.6/—	98.1/1.9
Haemophilus parainfluenzae (16)
Omadacycline	1	4	0.5 to 16	87.5e /6.2
Tetracycline	0.5	>8	0.25 to >8	68.8/12.5	68.8/31.2
Amoxicillin-clavulanate	0.5	2	0.12 to 4	100.0/0.0	93.8/6.2
Ampicillin	0.5	8	0.25 to >8	75.0/18.8	75.0/25.0
Azithromycin	2	4	0.25 to 8	93.8/—	93.8/—
Ceftriaxone	0.008	0.12	≤0.002 to 0.25	100.0/—	93.8/6.2
Levofloxacin	0.03	>2	0.008 to >2	87.5/—	81.2/18.8
Moraxella catarrhalis (913)
Omadacycline	≤0.12	0.25	≤0.12 to 0.5
Tetracycline	0.25	0.5	≤0.06 to >8	99.7/0.3	99.7/0.3
Amoxicillin-clavulanate	≤0.25	≤0.25	≤0.25 to 0.5	100.0/0.0	100.0/0.0
Azithromycin	≤0.03	≤0.03	≤0.03 to 1	99.9/—	99.9/0.1
Ceftriaxone	0.25	0.5	≤0.002 to 2	100.0/—	99.3/0.0
Levofloxacin	0.06	0.06	≤0.015 to 2	100.0/—	99.7/0.3
Penicillin	>4	>4	≤0.03 to >4

^aCriteria published by the Clinical and Laboratory Standards Institute (33) and The European Committee on Antimicrobial Susceptibility Testing (34). S, susceptibility; R, resistance; —, not applicable.

^bIn the absence of Clinical and Laboratory Standards Institute breakpoints, U.S. Food and Drug Administration breakpoints for S. pneumoniae community-acquired bacterial pneumonia were applied (35, 36).

^cUsing nonmeningitis breakpoints.

^dCriteria published by the Clinical and Laboratory Standards Institute (2019) for penicillin (oral penicillin) (33).

^eIn the absence of Clinical and Laboratory Standards Institute breakpoints, U.S. Food and Drug Administration breakpoints for Haemophilus spp. were applied (35, 36).